Can we make cannabis safer?

The Lancet Psychiatry

Volumn 4, Issue 8, 2017, Pages 643-648

  Englund, Amir ^a   Freeman, Tom P ^b   Murray, Robin M ^a   McGuire, Philip ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIS; ILLICIT DRUG; TETRAHYDROCANNABINOL; DRONABINOL; MEDICAL CANNABIS;

CANNABIS USE; CLINICAL RESEARCH; CRIMINAL JUSTICE; DRUG DEPENDENCE; DRUG POTENCY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK REDUCTION; UNITED KINGDOM; CANNABIS SMOKING; CHEMISTRY; DOSE RESPONSE; LEGISLATION AND JURISPRUDENCE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; HUMANS; MARIJUANA SMOKING; MEDICAL MARIJUANA;

EID: 85014091952     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30075-5     Document Type: Review

References (87)

1. Room, R, Fisher, B, Hall, W, Lenton, S, Reuter, P, Cannabis policy: moving beyond stalemate, 2010, Oxford University Press, Oxford, NY.
2. UNODC. World Drug Report 2015. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf, 2015 (accessed Oct 15, 2015).
3. Stockings, E, Hall, WD, Lynskey, M, et al. Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry 3 (2016), 280–296.
4. PHE. Young people's statistics from the National Drug Treatment Monitoring System (NDTMS): 1 April 2014 to 31 March 2015, 2015, Public Health England, London, 1–37.
5. UNODC. World Drug Report 2014. https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf, 2014 (accessed April 1, 2016).
6. EMCDDA. European Drug Report 2015. http://www.emcdda.europa.eu/edr2015, 2015 (accessed Oct 15, 2015).
7. Room, R, Legalizing a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. Addiction 109 (2014), 345–351.
8. Rosmarin, A, Eastwood, N, A quiet revolution: drug decriminalisation policies in practice across the globe. http://www.release.org.uk/publications/quiet-revolution-drug-decriminalisation-policies-practice-across-globe, 2012 (accessed May 29, 2013).
9. Lynskey, MT, Hindocha, C, Freeman, TP, Legal regulated markets have the potential to reduce population levels of harm associated with cannabis use. Addiction 111 (2016), 2091–2092.
10. Hanuš, LO, Meyer, SM, Muñoz, E, Taglialatela-Scafati, O, Appendino, G, Phytocannabinoids: a unified critical inventory. Nat Prod Rep 33 (2016), 1357–1392.
11. Small, E, Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev 81 (2015), 189–294.
12. Potter, DJ, A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 6 (2013), 31–38.
13. Cascini, F, Aiello, C, Di Tanna, G, Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5 (2012), 32–40.
14. Potter, DJ, Clark, P, Brown, MB, Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53 (2008), 90–94.
15. Hardwick, S, King, L, Home Office cannabis potency study. http://www.dldocs.stir.ac.uk/documents/potency.pdf, 2008 (accessed Nov 29, 2011).
16. Niesink, RJM, Rigter, S, Koeter, MW, Brunt, TM, Potency trends of Δ(9)-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–2015. Addiction 110 (2015), 1941–1950.
17. ElSohly, MA, Mehmedic, Z, Foster, S, Gon, C, Chandra, S, Church, JC, Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79 (2016), 613–619.
18. King, L, Carpentier, C, Griffiths, P, An overview of cannabis potency in Europe. http://www.emcdda.europa.eu/publications/insights/cannabis-potency, 2004 (accessed May 28, 2014).
19. Raber, JC, Elzinga, S, Kaplan, C, Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 40 (2015), 797–803.
20. Trecki, J, Gerona, RR, Schwartz, MD, Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373 (2015), 103–107.
21. Curran, HV, Freeman, TP, Mokrysz, C, Lewis, DA, Morgan, CJA, Parsons, LH, Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17 (2016), 293–306.
22. Haney, M, Malcolm, RJ, Babalonis, S, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41 (2016), 1974–1982.
23. Hindocha, C, Freeman, TP, Schafer, G, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25 (2015), 325–334.
24. Lawn, W, Freeman, TP, Pope, RA, et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology (Berl) 233 (2016), 3537–3552.
25. Morgan, CJA, Freeman, TP, Schafer, GL, Curran, HV, Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35 (2010), 1879–1885.
26. Lopez-Quintero, C, Pérez de los Cobos, J, Hasin, DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 115 (2011), 120–130.
27. Anthony, JC, The epidemiology of cannabis dependence. Roffman, RA, Stephens, RS, (eds.) Cannabis dependence: its nature, consequences and treatment, 2006, Cambridge University Press, Cambridge, 58–105.
28. Hall, W, The adverse health effects of cannabis use: what are they, and what are their implications for policy?. Int J Drug Policy 20 (2009), 458–466.
29. Freeman, TP, Winstock, AR, Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 45 (2015), 3181–3189.
30. Crippa, JAS, Hallak, JEC, Machado-de-Sousa, JP, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 38 (2013), 162–164.
31. Shannon, S, Opila-Lehman, J, Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas) 14 (2015), 31–35.
32. Trigo, JM, Lagzdins, D, Rehm, J, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 161 (2016), 298–306.
33. Allsop, DJ, Copeland, J, Lintzeris, N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 71 (2014), 281–291.
34. Di Forti, M, Morgan, C, Dazzan, P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 195 (2009), 488–491.
35. Di Forti, M, Sallis, H, Allegri, F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40 (2013), 1509–1517.
36. Di Forti, M, Marconi, A, Carra, E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238.
37. Schubart, CD, Sommer, IEC, van Gastel, WA, Goetgebuer, RL, Kahn, RS, Boks, MPM, Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130 (2011), 216–221.
38. Rigucci, S, Marques, TR, Di Forti, M, et al. Effect of high-potency cannabis on corpus callosum microstructure. Psychol Med 46 (2016), 841–854.
39. Demirakca, T, Sartorius, A, Ende, G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114 (2011), 242–245.
40. Yücel, M, Lorenzetti, V, Suo, C, et al. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry, 6, 2016, e710.
41. Weiland, BJ, Thayer, RE, Depue, BE, Sabbineni, A, Bryan, AD, Hutchison, KE, Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci 35 (2015), 1505–1512.
42. Pagliaccio, D, Barch, DM, Bogdan, R, et al. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 72 (2015), 994–1001.
43. French, L, Gray, C, Leonard, G, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 72 (2015), 1002–1011.
44. Schoeler, Monk, A, Sami, MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3 (2016), 215–225.
45. Schoeler, T, Petros, N, Di Forti, M, et al. Effects of continuation, frequency and type of cannabis use on relapse in the first two years following onset of psychosis: an observational study. Lancet Psychiatry 3 (2016), 947–953.
46. Cooper, K, Chatters, R, Kaltenthaler, E, Wong, R, Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess 19 (2015), 1–130.
47. Bianconi, F, Bonomo, M, Marconi, A, et al. Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychol Med 46 (2016), 995–1003.
48. Salamone, JD, Koychev, I, Correa, M, McGuire, P, Neurobiological basis of motivational deficits in psychopathology. Eur Neuropsychopharmacol 25 (2015), 1225–1238.
49. Silins, E, Horwood, LJ, Patton, GC, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 1 (2014), 286–293.
50. Stiby, AI, Hickman, M, Munafò, MR, Heron, J, Yip, VL, Macleod, J, Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction 110 (2015), 658–668.
51. Verweij, KJH, Huizink, AC, Agrawal, A, Martin, NG, Lynskey, MT, Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability?. Drug Alcohol Depend 133 (2013), 580–586.
52. Meier, MH, Caspi, A, Ambler, A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109 (2012), E2657–E2664.
53. Mokrysz, C, Landy, R, Gage, S, Munafo, M, Roiser, J, Curran, H, Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol 30 (2016), 159–168.
54. Jackson, NJ, Isen, JD, Khoddam, R, et al. Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci USA 113 (2016), e500–e508.
55. Schoeler, T, Kambeitz, J, Behlke, I, Murray, R, Bhattacharyya, S, The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med 46 (2016), 177–188.
56. Schreiner, AM, Dunn, ME, Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol 20 (2012), 420–429.
57. D'Souza, DC, Cortes-Briones, JA, Ranganathan, M, et al. Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 1 (2016), 60–67.
58. Hirvonen, J, Goodwin, RS, Li, CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17 (2012), 642–649.
59. Carbuto, M, Sewell, RA, Williams, A, et al. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 219 (2012), 885–896.
60. Lachenmeier, DW, Rehm, J, Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep, 5, 2015, 8126.
61. D'Souza, DC, Perry, E, MacDougall, L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004), 1558–1572.
62. D'Souza, DC, Ranganathan, M, Braley, G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33 (2008), 2505–2516.
63. Morrison, PD, Zois, V, McKeown, DA, et al. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39 (2009), 1607–1616.
64. Curran, HV, Brignell, C, Fletcher, S, Middleton, P, Henry, J, Cognitive and subjective dose-response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 164 (2002), 61–70.
65. Karniol, IG, Shirakawa, I, Kasinski, N, Pfeferman, A, Carlini, EA, Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 28 (1974), 172–177.
66. Zuardi, AW, Shirakawa, I, Finkelfarb, E, Karniol, IG, Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76 (1982), 245–250.
67. Morgan, CJA, Curran, HV, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192 (2008), 306–307.
68. Morgan, CJA, Gardener, C, Schafer, G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42 (2012), 391–400.
69. Leweke, FM, Schneider, U, Radwan, M, Schmidt, E, Emrich, HM, Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66 (2000), 175–181.
70. Morgan, CJA, Schafer, G, Freeman, TP, Curran, HV, Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197 (2010), 285–290.
71. Englund, A, Morrison, PD, Nottage, J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27 (2013), 19–27.
72. Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 (2010), 764–774.
73. Fusar-Poli, P, Allen, P, Bhattacharyya, S, et al. Modulation of effective connectivity during emotional processing by delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13 (2010), 421–432.
74. Hindocha, C, Freeman, TP, Ferris, JA, Lynskey, MT, Winstock, AR, No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry, 7, 2016, 104.
75. Hindocha, C, Freeman, TP, Winstock, AR, Lynskey, MT, Vaping cannabis (marijuana) has the potential to reduce tobacco smoking in cannabis users. Addiction, 111, 2016, 375.
76. Hindocha, C, Shaban, NDC, Freeman, TP, et al. Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. Drug Alcohol Depend 148 (2015), 165–171.
77. Ream, GL, Benoit, E, Johnson, BD, Dunlap, E, Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend 95 (2008), 199–208.
78. Valjent, E, Mitchell, JM, Besson, MJ, Caboche, J, Maldonado, R, Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 (2002), 564–578.
79. Gurillo, P, Jauhar, S, Murray, RM, et al. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2 (2015), 718–725.
80. van Gastel, WA, Maccabe, JH, Schubart, CD, et al. Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults. Psychol Med 43 (2013), 2393–2401.
81. Meier, MH, Hill, ML, Small, PJ, Luthar, SS, Associations of adolescent cannabis use with academic performance and mental health: a longitudinal study of upper middle class youth. Drug Alcohol Depend 156 (2015), 207–212.
82. Schauer, GL, Rosenberry, ZR, Peters, EN, Marijuana and tobacco co-administration in blunts, spliffs, and mulled cigarettes: a systematic literature review. Addict Behav 64 (2017), 200–211.
83. Daniulaityte, R, Nahhas, RW, Wijeratne, S, et al. “Time for dabs”: analyzing Twitter data on marijuana concentrates across the U.S. Drug Alcohol Depend 155 (2015), 307–311.
84. Van Laar, M, Van Der Pol, P, Niesink, R, Limitations to the Dutch cannabis toleration policy: assumptions underlying the reclassification of cannabis above 15% THC. Int J Drug Policy 34 (2016), 58–64.
85. Freeman, TP, Morgan, CJ, Hindocha, C, Schafer, G, Das, RK, Curran, HV, Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction 109 (2014), 1686–1694.
86. van der Pol, P, Liebregts, N, de Graaf, R, Korf, DJ, van den Brink, W, van Laar, M, Validation of self-reported cannabis dose and potency: an ecological study. Addiction 108 (2013), 1801–1808.
87. Grotenhermen, F, Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42 (2003), 327–360.